...
首页> 外文期刊>Infection and immunity >Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
【24h】

Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.

机译:在动物模型中口服或鼻内弗氏志贺氏菌2a和索氏志贺氏菌蛋白体-脂多糖疫苗的免疫原性和功效。

获取原文
           

摘要

Immunity against shigellosis has been shown to correlate with the presence of antibodies specific for Shigella lipopolysaccharide (LPS). We here propose a new candidate vaccine for shigellosis composed of purified Shigella flexneri 2a or Shigella sonnei LPS hydrophobically complexed with group C type 2b Neisseria meningitidis outer membrane protein proteosomes. Immunization of mice either orally or intranasally with this complex induced specific homologous anti-LPS antibodies in both intestinal and respiratory secretions as well as in sera. Strong anamnestic responses were found after two or three immunizations. LPS alone, alkaline-detoxified LPS, or alkaline-detoxified LPS complexed with proteosomes was not effective. Oral or intranasal immunization of guinea pigs with two or more doses of this proteosome-LPS vaccine elicited homologous protection against Shigella keratoconjunctivitis (Serény test). These data demonstrate that proteosomes can be used as an effective mucosal vaccine delivery system and that orally or intranasally administered acellular vaccines can protect against Shigella infections.
机译:已经证明抗志贺氏菌病的免疫力与志贺氏菌脂多糖(LPS)特异性抗体的存在有关。我们在此提出一种新的志贺氏菌病候选疫苗,该疫苗由纯化的弗氏志贺氏菌2a或索氏志贺氏菌LPS与C组2b型脑膜炎奈瑟氏球菌外膜蛋白蛋白疏水复合而成。用这种复合物口服或鼻内免疫小鼠可在肠道和呼吸道分泌物以及血清中诱导特异性同源的抗LPS抗体。两次或三次免疫后发现强烈的记忆消除反应。单独的LPS,与蛋白体复合的碱解毒LPS或碱解毒LPS无效。用两剂或更多剂这种蛋白体-LPS疫苗对豚鼠进行口服或鼻内免疫接种可引起针对志贺氏菌性角结膜炎的同源保护(Serény试验)。这些数据证明蛋白体可以用作有效的粘膜疫苗递送系统,并且口服或鼻内施用的脱细胞疫苗可以预防志贺氏菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号